Salomonsson Matilda Lampinen, Bondesson Ulf, Hedeland Mikael
Division of Analytical Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Biomedical Centre, P.O. Box 574, SE-751 23 Uppsala, Sweden.
Rapid Commun Mass Spectrom. 2008 Sep;22(17):2685-97. doi: 10.1002/rcm.3667.
For the first time chemical derivatization of isomeric drug glucuronides with 1,2-dimethylimidazole-4-sulfonyl chloride (DMISC) has been successfully applied as a tool for determining the site of conjugation. This provides a way to differentiate between glucuronide isomers containing aliphatic and phenolic hydroxyl groups. The analyses were performed with liquid chromatography/electrospray ion trap mass spectrometry (LC/ESI-MSn). DMISC has previously been shown to react selectively with phenols in estrogens, thus improving sensitivity in ESI-MS. The model compounds selected for this study were commercially available standards of formoterol, morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G). Formoterol glucuronides were produced with an enzymatic method in house. Both formoterol and morphine possess one phenolic and one aliphatic hydroxyl group where glucuronidation could take place. The product ion mass spectra of the native morphine glucuronides were indistinguishable due to the initial neutral loss of monodehydrated glucuronic acid (176 u). However, a significant difference between the isomers was observed with DMISC derivatization, as only the form with a free phenol, M6G, gave a detectable reaction product. Formoterol formed two detectable glucuronide isomers in the enzymatic reaction. Their respective sites of conjugation could not be directly determined from the product ion spectra. Reaction with DMISC, however, gave a detectable product with only one of the isomers. Based on previous experience of the preferred DMISC reactions with phenols, and interpretation of the fragmentation pattern of the derivative, it was concluded that the reactive isomer had a free phenol, and was thus conjugated on the aliphatic chain.
首次成功应用1,2 - 二甲基咪唑 - 4 - 磺酰氯(DMISC)对异构药物葡糖醛酸苷进行化学衍生化,作为确定结合位点的工具。这提供了一种区分含有脂肪族和酚羟基的葡糖醛酸苷异构体的方法。分析采用液相色谱/电喷雾离子阱质谱法(LC/ESI - MSn)进行。先前已证明DMISC能与雌激素中的酚类选择性反应,从而提高ESI - MS中的灵敏度。本研究选择的模型化合物是福莫特罗、吗啡、吗啡 - 3 - 葡糖醛酸苷(M3G)和吗啡 - 6 - 葡糖醛酸苷(M6G)的市售标准品。福莫特罗葡糖醛酸苷采用酶法在内部制备。福莫特罗和吗啡都具有一个酚羟基和一个脂肪族羟基,均可发生葡糖醛酸化。由于单脱水葡糖醛酸(176 u)的初始中性丢失,天然吗啡葡糖醛酸苷的产物离子质谱无法区分。然而,用DMISC衍生化时,异构体之间观察到显著差异,因为只有具有游离酚的形式,即M6G,产生了可检测的反应产物。福莫特罗在酶促反应中形成了两种可检测的葡糖醛酸苷异构体。它们各自的结合位点无法从产物离子光谱中直接确定。然而,与DMISC反应时,只有其中一种异构体产生了可检测的产物。基于先前DMISC与酚类优先反应的经验以及衍生物碎片模式的解释,得出反应性异构体具有游离酚,因此是在脂肪族链上结合的结论。